N/A N=38 Endorail in Long Lasting Colonoscopy
Colonoscopy · Incomplete Colonoscopy
Primary: Percentage of Incomplete Long-lasting Colonscopies — 0 % of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=51 Increasing Teen Access to Sexual and Mental Health Care
Health Care Utilization
Primary: Number of Participants With Any Healthcare Utilization From Baseline to 6 Months — 9; 7 Participants
N/A N=32 A Retrospective Review Evaluating the Matrix Pro Applicator for Treatment of Wrinkles
Wrinkle
Primary: Improvement in Facial Wrinkles — 24 Participants
N/A N=43 Do Terpenes Play a Role in the Stress-reducing Effects of a Forest Bathing Intervention?
Monoterpene Exposure During a Forest Bathing Intervention
Primary: Changes in the HF (ms^2) Component of HRV — 6.65; 6.48 ms^2 — p=0.914
Phase 4 N=47 Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions
Hepatic Disease
Primary: Accuracy of CEUS at Differentiating Focal Nodular Hyperplasia (FNH) From Hepatocellular Adenoma (HCA) — 66.7; 64.0; 71.9; 90.6 percentage of lesions
Phase 2 N=273 A Phase 2 Trial of OPC-64005 for Major Depressive Disorder
Major Depressive Disorder
Primary: Mean Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 6 of the Double-blind Treatment Period — -1.9; -1.6; -2.1; -3.9 Units…
Phase 2 N=74 Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial
Osteoarthritis, Knee
Primary: Number of Participants Experiencing One or More Treatment-Emergent Adverse Event — 28; 33 Participants — p=>0.9
Phase 4 N=107 Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Radiocontrast-induced Nephropathy
Primary: Changes in Renal Blood Flow — 9590.8; 5105.4; 8529.4; 5228.4 h.mL/min
N/A N=21 Physical Activity and Pacemaker Study
Physical Activity · Pacemaker · Cardiovascular Diseases
Primary: Physical Activity Level as Measured by Embedded Accelerometer — 1.97; 1.77 active hours/day
Phase 2 N=54 A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
Hepatitis B, Chronic
Primary: Percentage of Participants With Functional Cure: Hepatitis B Surface Antigen (HBsAg) Seroclearance at 24 Weeks After Stopping All Study Interventions at the End of…
Phase 1 N=8 Boiled Peanut Oral Immunotherapy
Peanut Hypersensitivity
Primary: Increase in Tolerance to Peanut in Pediatric Patients With Peanut Hypersensitivity Reported as the Percentage of Participants Successfully Desensitized. — 75 percentage…
Phase 2 N=223 Plasma Therapy of COVID-19 in Severely Ill Patients
SARS-CoV-2 Infection
Primary: Number of Participants With Day 28 Severity Outcomes Using a 7-point Ordinal Scale of Clinical Status — 108; 48; 3; 2 Participants
Phase 3 N=8 Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
Bladder Cancer · Urothelial Carcinoma · Urothelial Carcinoma Bladder
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation, and TEAEs of Special Interest. — 8; 3; 2; 7…
N/A N=43 Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
Relapsing Remitting Multiple Sclerosis
Primary: Relapse Free Survival at Month 12 — 95.2 Percentage of Participant Survival Rate
Phase 1 N=12 Effect of Prebiotics on the Gut Microbiome Profile and Beta Cell Function
Type 1 Diabetes
Primary: Change in the Gut Microbiome Profile — 818.5; 229; 1610; 177 species count